Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-02

Evommune (EVMN)

CEO Luis Peña was paid $11,022,670 in fiscal year 2025, ↑ up 48.1% from fiscal year 2024 (SEC filing 0001193125-26-166747 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$11,022,670 ↑
Luis Peña total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
—
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Luis Peña (Chief Executive Officer), FY2025 total compensation $11,022,670 (base salary $588,462) [exec_comp, SEC accession 0001193125-26-166747, filed 2026-04-21]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

EVMN's next annual pay disclosure, estimated April 21, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Luis Peña$588,462$740,675$0$9,693,533$0$0$0$11,022,670
Chief Executive Officer
Gregory Moss515,042508,43303,570,591006,9004,600,966
Chief Business & Legal Officer
Kyle Carver501,875496,65803,399,210006,9004,404,643
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Luis Peña$11,022,670$7,444,605—↑ +3,578,065
Gregory Moss4,600,9661,355,474—↑ +3,245,492
Kyle Carver4,404,6431,237,071—↑ +3,167,572

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Evommune's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper EVMN reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against EVMN
No companies currently name EVMN as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Gregory MossChief Business & Legal Officer$4,600,966
Kyle CarverCFO$4,404,643
Luis PeñaCEO$11,022,670
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Arthur KirschIndependent Director$451,244
Benjamin F. McGraw III, Pharm.DChair of the Board$490,827
David E. Cohen, M.D., M.P.HIndependent Director$484,577
Derek DiRocco, Ph.DIndependent Director—
Eugene A. Bauer, M.DDirector—
Felice Verduyn-van WeegenIndependent Director—
François Beaubien, Ph.D., C.F.AFormer director (through FY2025)—
Rob Hopfner, R.Ph., Ph.DIndependent Director—
Yuexin YuFormer director (through FY2025)—
02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Luis PeñaRSU141,753—$2,426,811
Gregory MossRSU55,845—956,066
Kyle CarverRSU54,469—932,509
Luis PeñaOption41,1293.07—
Kyle CarverOption7,4043.07—
Luis PeñaOption27,8133.58—
Luis PeñaOption68,0413.84—
Kyle CarverOption279,40816—
Luis PeñaOption12,3951.71—
Luis PeñaOption218,0812.99—
Luis PeñaOption796,84116—
Luis PeñaOption444,9922.99—
Gregory MossOption16,7303.07—
Gregory MossOption9,5673.58—
Kyle CarverOption8,3443.58—
Gregory MossOption23,1343.84—
Gregory MossOption4,2141.71—
Gregory MossOption34,9141.71—
Gregory MossOption85,9142.99—
Gregory MossOption293,49616—
Kyle CarverOption20,4133.84—
Kyle CarverOption3,5701.71—
Kyle CarverOption83,7992.99—
05

Incentive-plan design — the Compensation Discussion & Analysis

The company's compensation philosophy is designed to align named executive officers' interests with those of stockholders and to retain and incentivize them over the long-term. Base salaries are established based on role, responsibilities, and market levels, while equity-based incentive awards serve as a retention measure tied to continuous service and corporate goals.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantAon Consulting, Inc.
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-02—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-02—a

a. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Benjamin F. McGraw III, Pharm.DIndependent · Board Chair · Audit · Compensation (Chair) · Nominating and Corporate Governance · Science and Technology · Not standing for re-election$50,833—$439,994——$490,827
David E. Cohen, M.D., M.P.HIndependent · Compensation · Nominating and Corporate Governance (Chair) · Science and Technology (Chair) · Not standing for re-election44,583—439,994——484,577
Arthur KirschIndependent · Audit (Chair) · Compensation · Not standing for re-election11,250—439,994——451,244
Eugene A. Bauer, M.DEmployee director · Science and Technology—————0
Rob Hopfner, R.Ph., Ph.DIndependent · Audit · Science and Technology · Not standing for re-election0—0——0
François Beaubien, Ph.D., C.F.AIndependent · Not standing for re-election · Departed during FY0—0——0
Felice Verduyn-van WeegenIndependent · Nominating and Corporate Governance · Science and Technology · Not standing for re-election0—0——0
Luis PeñaEmployee director · Nominating and Corporate Governance—————0
Derek DiRocco, Ph.DIndependent · Science and Technology · Not standing for re-election · Newly elected0—0——0
Yuexin YuIndependent · Not standing for re-election · Departed during FY0—0——0
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$440,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$106,666
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$106,666

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Evommune2025Luis Peña$588,462$0$9,693,533$0$11,022,670

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Evommune in fiscal 2025?
As disclosed, Luis Peña (Chief Executive Officer) was the highest-paid executive at Evommune in fiscal 2025, with total compensation of $11,022,670.
How much does Evommune spend in total on board compensation for fiscal 2025?
As disclosed, Evommune reported total board compensation of $106,666 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Luis PeñaDEF 14A2026-04-210001193125-26-166747Section “Executive Compensation”. As printed: 11,022,670. Filing ↗machine: r2 · c20 · span 343619–343629
2Section 01, Gregory MossDEF 14A2026-04-210001193125-26-166747Section “Executive Compensation”. As printed: 4,600,966. Filing ↗machine: r4 · c20 · span 359027–359036
3Section 01, Kyle CarverDEF 14A2026-04-210001193125-26-166747Section “Executive Compensation”. As printed: 4,404,643. Filing ↗machine: r6 · c20 · span 374439–374448
4Section 08, Benjamin F. McGraw III, Pharm.DDEF 14A2026-04-210001193125-26-166747Section “Director Compensation”. As printed: 490,827. Filing ↗machine: span 669114–669323
5Section 08, David E. Cohen, M.D., M.P.HDEF 14A2026-04-210001193125-26-166747Section “Director Compensation”. As printed: 484,577. Filing ↗machine: span 673734–673943
6Section 08, Arthur KirschDEF 14A2026-04-210001193125-26-166747Section “Director Compensation”. As printed: 451,244. Filing ↗machine: span 690352–690561
7Section 08, Eugene A. Bauer, M.DDEF 14A2026-04-210001193125-26-166747Section “Director Compensation”. As printed: 0. Filing ↗
8Section 08, Rob Hopfner, R.Ph., Ph.DDEF 14A2026-04-210001193125-26-166747Section “Director Compensation”. As printed: 0. Filing ↗
9Section 08, François Beaubien, Ph.D., C.F.ADEF 14A2026-04-210001193125-26-166747Section “Director Compensation”. As printed: 0. Filing ↗
10Section 08, Felice Verduyn-van WeegenDEF 14A2026-04-210001193125-26-166747Section “Director Compensation”. As printed: 0. Filing ↗
11Section 08, Luis PeñaDEF 14A2026-04-210001193125-26-166747Section “Director Compensation”. As printed: 0. Filing ↗
12Section 08, Derek DiRocco, Ph.DDEF 14A2026-04-210001193125-26-166747Section “Director Compensation”. As printed: 0. Filing ↗
13Section 08, Yuexin YuDEF 14A2026-04-210001193125-26-166747Section “Director Compensation”. As printed: 0. Filing ↗
14Section 06, 2026 voteForm 8-K2026-06-020001193125-26-253482Item 5.07 · say-on-pay result. As reported: —. Filing ↗
15Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
16Section 09b board cost (computed)Computed——Cash 106,666 + equity 0 + all other 0 = 106,666, summed across the director compensation table rows.machine: formula: Σ = 106,666
17Evommune (subject), Section 10b CEO totalDEF 14A2026-04-210001193125-26-166747CEO total compensation as printed in Evommune's own proxy. As printed: 11,022,670. Filing ↗machine: r2 · c20 · span 343619–343629

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.